Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 6:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–40 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Intravitreal dexamethasone implant Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

One Year Trial Evaluating Safety of Ozurdex With Eylea

NCT03984110
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ozurdex, Eylea
Drug
Lead sponsor
Texas Retina Associates
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Sep 29, 2026, 6:10 PM EDT
Completed Phase 4 Interventional Results available

Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema

NCT02471651
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone intravitreal implant (0.7 mg), Intravitreal anti-VEGF injection
Drug
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Bakersfield, California • Oxnard, California • Santa Barbara, California + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Sep 29, 2026, 6:10 PM EDT
Completed No phase listed Observational Results available

Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)

NCT03889444
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone intravitreal implant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2020 · Synced Sep 29, 2026, 6:10 PM EDT
Completed Phase 3 Interventional Results available

Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial

NCT02623426
View directory record Official record
Conditions
Uveitis, Macular Edema
Interventions
Dexamethasone intravitreal implant 0.7 mg, Intravitreal Methotrexate 400 µg, Intravitreal Ranibizumab 0.5 mg
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2023 · Synced Sep 29, 2026, 6:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.

NCT01449682
View directory record Official record
Conditions
Retinal Vein Occlusion, Macular Edema
Interventions
Ozurdex
Drug
Lead sponsor
Retina Macula Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 29, 2026, 6:10 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina

NCT04976777
View directory record Official record
Conditions
Macular Edema
Interventions
Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
Device · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Glendale, California • North Dartmouth, Massachusetts • Independence, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 29, 2026, 6:10 PM EDT
Not listed Not applicable Interventional

Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion

NCT01581151
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Dexamethasone intravitreal implant, Monthly Ranibizumab
Drug
Lead sponsor
Brian Burke, MPH
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2015 · Synced Sep 29, 2026, 6:10 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF

NCT01946399
View directory record Official record
Conditions
Retinal Vein Occlusion (RVO), Macular Edema
Interventions
Ozurdex implant
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 29, 2026, 6:10 PM EDT
Not listed Phase 4 Interventional

Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME

NCT04038125
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy, Retinal Ischemia
Interventions
Ozurdex Drug Implant Product
Drug
Lead sponsor
Retina Macula Specialists of Miami, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
North Miami Beach, Florida • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 29, 2026, 6:10 PM EDT
Not listed Phase 4 Interventional

INtravitreal and Aqueous Dexamethasone Levels After DEXtenza

NCT04529512
View directory record Official record
Conditions
Ocular Disease Requiring Surgery
Interventions
DEXTENZA®
Drug
Lead sponsor
Nathan Steinle
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Paso Robles, California • San Luis Obispo, California • Santa Maria, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 29, 2026, 6:10 PM EDT
Completed No phase listed Observational

An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)

NCT02188173
View directory record Official record
Conditions
Macular Edema
Interventions
dexamethasone 700 ㎍ intravitreal implant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
18
States / cities
Phoenix, Arizona • San Francisco, California • Santa Ana, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 31, 2016 · Synced Sep 29, 2026, 6:10 PM EDT
Completed Not applicable Interventional Results available

Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)

NCT01231633
View directory record Official record
Conditions
Macular Edema, Central Retinal Vein Occlusion
Interventions
Ozurdex, Avastin
Drug
Lead sponsor
Long Island Vitreoretinal Consultants
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Toms River, New Jersey • Great Neck, New York • Hauppauge, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Sep 29, 2026, 6:10 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion

NCT01827722
View directory record Official record
Conditions
Macular Edema, Central Retinal Vein Occlusion
Interventions
Ozurdex, Ranibizumab, Combination Ozurdex with Ranibizumab PRN
Drug
Lead sponsor
Valley Retina Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
5
States / cities
Beverly Hills, California • Lakeland, Florida • Winter Haven, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 29, 2026, 6:10 PM EDT
Completed Phase 2Phase 3 Interventional

Ozurdex for Macular Edema Post Membrane Peeling

NCT01273727
View directory record Official record
Conditions
Epiretinal Membrane, Cellophane Maculopathy, Macular Edema, Retinal Edema
Interventions
dexamethasone
Drug
Lead sponsor
Retina Specialists, PC
Other
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Sep 29, 2026, 6:10 PM EDT
Completed Phase 1 Interventional

Dexamethasone Implant for Retinal Detachment in Uveal Melanoma

NCT04082962
View directory record Official record
Conditions
Exudative Retinal Detachment and Uveal Melanoma
Interventions
Dexamethasone intravitreal implant
Drug
Lead sponsor
Ivana K. Kim
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 29, 2026, 6:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial

NCT02374060
View directory record Official record
Conditions
Macular Edema, Uveitis
Interventions
Periocular triamcinolone 40 mg, Intravitreal triamcinolone 4 mg, Dexamethasone intravitreal implant
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
23
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Sep 29, 2026, 6:10 PM EDT